Evaluation of the Efficacy in Increasing Sexual Arousal, Safety and Tolerability of BZ371A in Women With Sexual Arousal Disorder

Inclusion Criteria: * Women aged between 21 and 65 years; * Premenopausal or postmenopausal women may be included; * May or may not be using female sex hormones (estrogen with or without progesterone, or their derivatives); * Women who have previously had sexual experiences with orgasm, desire, and arousal, for a minimum period of two years; * FSD, defined according to DSM-IV diagnostic criteria, that is, the presence of a persistent or recurrent inability to achieve or maintain adequate physiological sexual arousal during sexual activity, meaning a reduction or absence of genital response (lubrication, clitoral swelling, or other genital responses such as genital pleasure sensations); * FSD causes significant personal distress and/or interpersonal difficulty; * FSFI questionnaire meeting criteria for female sexual dysfunction, i.e., \<26.5; * Stable relationship for more than 6 months, with a sexually active partner who is present (cannot be traveling, for example) during the treatment period; * Ability to read and understand the Informed Consent Form (ICF) and to complete the questionnaires. Exclusion Criteria: * Women who do not agree to use a contraceptive method and who have the capacity to become pregnant during the study; * Women who do not agree to attempt sexual activity at least twice a week while taking the study medication; * Serious relationship problems, defined as a CSI-16 score below 51.5, of non-sexual origin, and which, in the investigator's opinion, may …